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Abstract
Background: Since the introduction of antipsychotics, especially the so called atypicals, the treatment of schizophrenia has
shown important improvements. At the present time, it is preferred to label clozapine and other antipsychotics sharing similar
profiles as second-generation antipsychotics (SGAs). These medications have been proposed by some experts as a first line
treatment for schizophrenia.
It is critical to have reliable data about antipsychotic prescription in Mexico and to create management guidelines based on
expert meetings and not only on studies carried out by the pharmaceutical industry. Only this approach will help to make the
right decisions for the treatment of schizophrenia.
Methods: A translated version of Rabinowitz's survey was used to evaluate antipsychotic prescription preferences and patterns
in Mexican psychiatrists.
The survey questionnaire was sent by mail to 200 psychiatrists from public institutions and private practice in Mexico City and
Guadalajara, Mexico.
Results: Recommendations for antipsychotics daily doses at different stages of the treatment of schizophrenia varied widely.
Haloperidol was considered as the first choice for the treatment of positive symptoms. On the contrary, risperidone was the
first option for negative symptoms. For a patient with a high susceptibility for developing extrapyramidal symptoms (EPS),
risperidone was the first choice.
It was also considered that SGAs had advantages over typical antipsychotics in the management of negative symptoms, cognitive
impairment and fewer EPS.
Besides, there was a clear tendency for prescribing typical antipsychotics at higher doses than recommended and inadequate
doses for the atypical ones.
Conclusions: Some of the obstacles for the prescription of SGAs include their high cost, deficient knowledge about their
indications and dosage, the perception of their being less efficient for the treatment of positive symptoms and the resistance of
some Mexican physicians to change their prescription pattern. It is necessary to reach a consensus, in order to establish and
standardize the treatment of schizophrenia, based on the information reported in clinical trials and prevailing economic
conditions in Mexico.
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Background
Since the introduction of antipsychotics, especially the so-
called atypicals, the treatment of schizophrenia has
shown important improvements. Antipsychotic medica-
tions were initially called neuroleptics because of their
effect on mobility; nowadays they are known as first-gen-
eration antipsychotics (FGAs) [1]. Later on, clozapine, a
drug with good antipsychotic profiles but without
extrapyramidal side effects, emerged and was called an
atypical antipsychotic [2]. Clozapine and other antipsy-
chotics with similar properties are now called second gen-
eration antipsychotics (SGAs).
In different treatment guidelines, SGAs have been consid-
ered as the first therapeutical option in schizophrenia [3-
6], because they have been associated with a lower proba-
bility of EPS development, and possibly with a better effi-
cacy over negative symptoms, depression and hostility
[7]. These medications have also been found to be associ-
ated with less cognitive impairment, even producing
improvement in some cases [8].
In Mexico, SGAs have been available for the treatment of
psychosis since 1994, when risperidone and clozapine
were introduced. Olanzapine and quetiapine were added
in 1996 and 1997, respectively; and finally, ziprasidone
was introduced in 2001. New SGAs have been added to
actual treatment options, being amisulpride one of the
most recently introduced. This medication is a dopamine
D2/D3 receptor antagonist with similar properties to SGAs
[9]. In 2003, the introduction of aripiprazole, a partial
dopamine agonist, raised polemic due to its classification,
since it has a different mechanism of action. Some clini-
cians consider it as a third-generation antipsychotic or a
pioneer of the so called dopamine-serotonin system stabi-
lizers [10]. Other drugs like amoxapine, which have a
lower direct cost, are being evaluated for their use since
they have shown similar profiles to SGAs [11].
Pharmaceutical industries spend around 23% to 30% of
the actual cost of a drug on its promotion [12]. This is
basically directed to advertisements for physicians, trying
to convince them to prescribe a particular drug. This strat-
egy has generated better results rather that promoting the
drug directly with the patients or their families. On the
other hand, psychiatrists (as well as other physicians)
update their medical knowledge through information
provided by the industry in medical courses, visits at their
offices, and briefs of medical articles. Clinical trials spon-
sored by the pharmaceutical industry represent nowadays
a good proportion of the medical literature [13]. It has
been estimated that between 89% to 98% of published
clinical trials comparing two different medications tend to
show positive results (efficacy and safety) of the product
from the pharmaceutical house sponsoring the study [14-
16]. To counteract this tendency, CATIE, a long-term fol-
low-up study in the US [17], is comparing the use of dif-
ferent SGAs with perfenazine. This study does not involve
any pharmaceutical industry and may provide reliable
information for a better treatment of schizophrenia.
The previous information underscores the importance of
having reliable data regarding antipsychotic prescription
in our country and the need to create management guide-
lines based on expert meetings and not only on studies
carried out by the pharmaceutical industry. This will help
physicians in making the right decisions for the treatment
of schizophrenia.
The aim of this study was to determine the antipsychotic
preferences and patterns of prescription for the treatment
of schizophrenia among a group of Mexican psychiatrists.
Methods
A survey developed by Rabinowitz et al [18] was trans-
lated into Spanish, with permission of the author, and
used to evaluate antipsychotic prescription preferences
and patterns.
Table 1: Daily dose prescriptions in different stages of the treatment of schizophrenia.
Initial Dose (mg/day) Maintenance (patient who recovered 
from an acute episode) (mg/day)
Maximum dosage for chronic severely ill 
psychotic patient (mg/day)
Risperidone 3.3(2.1) 1–12 4.1 (1.6) 1–12 6.9 (2.8) 1–20
Olanzapine 9.2 (3.7) 2–20 9.5 (3.5) 2.5–20 15.5 (7.2) 3–40
Quetiapine 139.6(156.3) 20–800 208.1 (141.3) 15–775 371.5 (209.9) 15–800
Clozapine 109.1 (128.6) 10–600 194.1 (126.1) 10–600 358.1 (225.6) 10–900
Haloperidol 16.3 (17.1) 1–150 14.3 (10.9) 3–90 30.3 (23.6) 1–150
Trifluoperazine 15.6 (15.1) 1–120 17.1 (15.7) 3–120 30.1(20.5) 5–100
Perfenazine 15.1 (12.8) 4–96 16.4 (13.7) 2–96 23.1 (15.9) 4–90BMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/12
Page 3 of 7
(page number not for citation purposes)
This survey assesses the knowledge regarding the prescrip-
tion of antipsychotics by inquiring the following aspects:
1) Mean dosage of several antipsychotics at different
stages of the treatment of schizophrenia, 2) perception of
the advantages of typical and atypical antipsychotics, 3)
preferences for the prescription of antipsychotics in differ-
ent clinical conditions (e.g. predominantly negative
symptoms), 4) patterns of prescription for concomitant
therapy, and 5) treatment strategies in different clinical
situations.
Only those antipsychotics available at the time of the
study were included in the survey; drugs such as amisul-
pride, ziprasidone and aripiprazole were excluded. Only
the most frequently used FGAs were included.
The sample comprised 200 psychiatrists from public insti-
tutions and private practice in Mexico City and Guadala-
jara, Mexico. The selected sample represented 10% of
these specialized physicians in the country. They were ran-
domly chosen from the Mexican Association of Psychiatry
register. Psychiatrists were asked to answer the question-
naire and to return it closed and without identification to
preserve confidentiality.
Analysis
Frequencies and percentages were used for descriptive
analysis of categorical variables and means and standard
deviations (+/-) for continuous variables.
Results
One hundred and forty eight questionnaires were
returned, 74% of the total. Within the physicians who
returned the questionnaires, mean age was 43.9 +/- 10.6
year old (range 25 to 73 years) and 113 (76.4%) were
male. Seventy nine (53.4%) were certified by the Mexican
Board of Psychiatry 60 (40.5%) were not, and 9 (6.1%)
were residents. About 80% of those inquired worked at a
public institution. There were no differences in response
rates between psychiatrists from public and private
institutions.
Prescription dosages for different stages of schizophrenia
treatment given by surveyed psychiatrists are shown in
Table 1. The initial and maintenance doses, as well as
those prescribed for chronically ill patients were registered
over a wide range on the survey. Perceptions about FGAs
and SGAs advantages and disadvantages were divided in
efficacy, safety and cost-benefit (Table 2). Haloperidol
was considered the first choice for the treatment of posi-
tive symptoms followed by risperidone. On the other
hand, risperidone was reported as a first line drug for the
treatment of negative symptoms, while olanzapine was
second.
For the treatment of first-psychotic episode, haloperidol
was preferred as first choice and olanzapine as the second.
For chronic schizophrenia, the most frequently prescribed
drug was risperidone followed by olanzapine. For the
treatment of psychosis in the elderly, the first choice was
risperidone; haloperidol and olanzapine were considered
second options. For patients prone to EPS, psychiatrists
preferred risperidone as a first option followed by olanza-
pine. Risperidone was also the first and second choice for
the treatment of resistant schizophrenia. Finally, for acute
relapse episodes, the first choice was haloperidol and the
second was risperidone.
It is a common practice to combine antipsychotic therapy
with other drugs. Table 3 shows prescription patterns of
these drugs.
The last section of the survey included information
obtained by direct questions or clinical vignettes evaluat-
ing knowledge about treatment switching strategies, typi-
cal daily dosages for particular clinical conditions (e.g.
early psychosis, refractory psychosis, etc.), the concept of
resistant schizophrenia, recommended treatment dura-
tion and the most effective atypical antipsychotic for
relapse prevention 'Questionnaire [see Additional file 1]'.
Discussion
Psychiatrists' perception about SGAs
The results of the survey showed that Mexican psychia-
trists are aware of the higher efficacy of SGAs on negative
symptoms as well as their lower incidence of EPSs, aka-
thisia and tardive dyskinesia. However, they considered
these antipsychotics less effective on positive symptoms
than FGAs. Half of those surveyed answered that SGAs
could reduce the cost of treatment but the main limitation
for their use was their high cost. In fact, most psychiatrists
would prescribe these drugs to patients if their cost per
patient were lower (i.e. less than $50 USD a month).
Antipsychotic prescription patterns
According to the results of the survey, there is a wide
knowledge about the indications and dose ranges recom-
mended in the literature for risperidone and olanzapine
[19-22]. On the other hand, less than half of the surveyed
knew the recommended average doses of clozapine and
quetiapine and the trend was to prescribe lower doses
than those reported on international studies [23-30]. This
may be explained by the fact that risperidone and olanza-
pine have been available for a longer time and physicians
have more information about them. The use of clozapine
was found to be limited due to its high direct cost and side
effects profile [28].
Two possible explanations can be offered for the wide
range of FGA doses reported for the different phases ofBMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/12
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treatment among particular clinical scenarios. First, the
persistence of FGA prescription at higher doses than the
recommended on international consensus [3-6] may be
related to the belief on "rapid neuroleptization" or
impregnation for the management of an aggressive and
agitated psychotic patient; and second, the use of low
doses of these drugs reflects the preference for prescribing
threshold or minimum effective doses. Many studies on
the effectiveness of this approach have been published
[31-36]. This strategy is based on the finding that clinical
response is reached with 65% dopamine D2 receptor occu-
pancy. If this threshold is surpassed by 72% high prolactin
levels are reached and if it surpasses 78% the risk of EPS
increases [37-41]. In our country some studies support the
use of minimum dosages of these medications as a first
choice for the treatment of acute and chronic schizophre-
nia [42-44]. Not controlled, open trials comparing the
efficacy of minimum effective doses of haloperidol with
SGAs reported similar response rates [45-48].
Another important issue raised by the survey was the
duration of the treatment with a given antipsychotic
before considering it a treatment failure. A common mis-
take is to give the antipsychotic for a short time (e.g. two
weeks). Current guidelines indicate that one must wait at
least 6 weeks for assessing a clinical response; the results
of our survey showed that 78% of the physicians do wait
this time.
A good consensus on the strategies to change the pre-
scribed antipsychotic due to a lack of response or severe
side effects was observed in the survey. These strategies
Table 2: Perception concerning advantages and disadvantages of typical and atypical antipsychotics.
A lot Somewhat No
Atypicals are more effective in reducing negative symptoms 69.9% 27.4% 2.7%
Atypicals are more effective in reducing positive symptoms 34.9% 46.6% 18.5%
Atypicals are more effective in treating cognitive impairment 62.3% 31.5% 6.2%
Atypicals are more effective in improving social function 76.7% 21.2% 2.1%
Atypicals are more effective in improving occupational function 68.5% 27.4% 4.1%
Atypicals reduce treatment cost (use of inpatient and outpatient services) 51.4% 32.2% 16.4%
Atypical antipsychotics cause less EPS 80.3% 19% 0.7%
Atypical antipsychotics cause less tardive dyskinesia 76% 21.9% 2.1%
Atypical antipsychotic treatment requires less use of antiparkinsonian drugs 78.2% 19.7% 2%
Assuming that there were no restrictions in prescribing and obtaining atypical antipsychotics what would 
be your first recommendation choice?
Atypical Typical
87.8% 12.2%
Assuming that the atypical antipsychotic would cost the patient $50 a month and the typical one is free, 
would you prescribe the atypical?
Yes No
77.4% 22.6%
Assuming that the atypical antipsychotic would cost the patient $200 and the typical one is free, would 
you prescribe the atypical?
Yes No
35.6% 64.4%
Assuming that the atypical antipsychotic would cost the patient $500 and the typical one is free, would 
you prescribe the atypical?
Yes No
20% 80%
If there was a choice of giving a partial treatment responder an atypical antipsychotic for six months or a 
typical antipsychotic for 6 months and 6 months of a sheltered workshop what would you choose?
Atypical Sheltered workshop
66.4% 33.6%
Table 3: Frequency of second-generation antipsychotics in combination with other psychoactive drugs.
Never Sometimes Often
Typical antipsychotics 46.8% 48.2% 5%
Serotonin reuptake inhibitors 7.6% 66% 26.4%
Tricyclic antidepressants 36.9% 53.9% 8.5%
Benzodiazepines 6.8% 49.7% 42.9%BMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/12
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consisted in: a) to start the new antipsychotic and raise the
dose to therapeutic levels, while gradually lowering the
dose of previous antipsychotic, and b) to instate a wash-
out period before starting the new antipsychotic [49].
Both strategies are recommended and the selection
depends on the clinical condition of the patient, the pres-
ence of side effects, or the risk of appearance of new
adverse events.
Regarding concomitant treatment, it was observed that
many physicians had a tendency to prescribe serotonin
reuptake inhibitors and benzodiazepines. The antidepres-
sants are frequently prescribed for comorbid depression.
Sertraline, a SSRI, has shown efficacy for the treatment of
major depression in schizophrenic patients [50,51]. On
the other hand, benzodiazepines are first line drugs for
the management of agitation or aggression in psychotic
patients [5]. Although the indications for the use of these
drugs have been clearly established, it is not possible from
our results to infer the reasons the surveyed clinicians had
for prescribing these drugs.
Regarding the maintenance phase, a clear and adequate
estimation was found with regard to the duration of treat-
ment for a multi-episode patient, but not in the case of a
first-episode patient. In this case, the prevailing practice
was to maintain the treatment for at least two years; if
patients have gone into remission during this period,
treatment suspension must be considered [52]. Neverthe-
less, only 15% to 25% of first-episode patients will not
present a relapse during the first 5 years of treatment [53-
56]. A 5-year relapse is around 86%, due mainly to treat-
ment abandonment [57].
According to the information collected on refractory
schizophrenia, the first treatment choice among surveyed
psychiatrists was risperidone; the dosages of different
antipsychotics for this type of patients varied widely. Until
now, clozapine represents the first treatment choice for a
refractory patient and can be administered to a maximum
dose of 900 mg/day; this information is not commonly
handled by the physicians. Another important issue
found in our results was the association of a SGA with a
typical one for the treatment of partial response or lack of
response. There is no evidence that this strategy increases
response. Addition of lithium or valproate has been rec-
ommended [3-6].
The limitations of this study were that the survey did not
include all FGAs currently available in Mexico nor SGAs
more recently introduced; therefore, prescription patterns
of other drugs, probably frequently used, were missed.
The survey made no difference between depot (long-act-
ing injectable medication) and oral drugs. Also, it did not
include differences in treatment between inpatients and
outpatients, nor the reasons for prescribing concomitant
drugs. Further studies are needed to include these varia-
bles and to increase the sample size.
Conclusions
From the results of this survey it can be concluded that
Mexican psychiatrists are aware of the advantages of SGAs
in the treatment of schizophrenia, although they perceive
SGAs as being less efficacious for the treatment of positive
symptoms than FGAs. In addition, the high direct cost of
SGAs is a limitation for their prescription.
Surveyed psychiatrists exhibited different levels of knowl-
edge on clinical concepts (e.g. refractory schizophrenia)
and on prescription guidelines of some SGAs. In addition,
it was also found that FGA prescription is still determined
by old concepts, such as "rapid neuroleptization" and that
there is resistance in some Mexican physicians for chang-
ing their pattern of prescription. Similar difficulties have
been encountered in other cities of Europe and develop-
ing countries.
It is necessary to reach a consensus to establish and stand-
ardize the treatment of schizophrenia, based on the infor-
mation reported in clinical trials and on the economic
conditions of the country to avoid inadequate treatments
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